Drug Profile


Alternative Names: 2S,4R-ketoconazole; COR-003; NormoCort; RECORLEV

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Cortendo
  • Developer Strongbridge Biopharma
  • Class Chlorobenzenes; Dioxolanes; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Steroid 11-beta-hydroxylase inhibitors; Steroid 17-alpha-hydroxylase inhibitors; Steroid 21 hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cushing syndrome

Most Recent Events

  • 23 Dec 2016 Strongbridge Biopharma plans the phase III LOGICS trial in Cushing syndrome
  • 04 Apr 2016 Strongbridge Biopharma completes a phase I trial in Cushing syndrome in USA
  • 07 Dec 2015 Strongbridge Biopharma receives patent allowance for levoketoconazole in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top